{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T23:59:22Z","timestamp":1768003162970,"version":"3.49.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,9,17]],"date-time":"2021-09-17T00:00:00Z","timestamp":1631836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,9,17]],"date-time":"2021-09-17T00:00:00Z","timestamp":1631836800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1007\/s10067-021-05921-2","type":"journal-article","created":{"date-parts":[[2021,9,17]],"date-time":"2021-09-17T22:02:40Z","timestamp":1631916160000},"page":"557-566","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["The effectiveness of tocilizumab in treating refractory adult-onset Still\u2019s disease with dichotomous phenotypes: IL-18 is a potential predictor of therapeutic response"],"prefix":"10.1007","volume":"41","author":[{"given":"Kuo-Tung","family":"Tang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chia-Wei","family":"Hsieh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hsin-Hua","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi-Ming","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shih-Hsin","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Po-Hao","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joung-Liang","family":"Lan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1266-1423","authenticated-orcid":false,"given":"Der-Yuan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,9,17]]},"reference":[{"issue":"6","key":"5921_CR1","first-page":"1139","volume":"14","author":"A Ohta","year":"1987","unstructured":"Ohta A, Yamaguchi M, Kaneoka H, Nagayoshi T, Hiida M (1987) Adult Still\u2019s disease: review of 228 cases from the literature. J Rheumatol 14(6):1139\u20131146","journal-title":"J Rheumatol"},{"issue":"1","key":"5921_CR2","doi-asserted-by":"publisher","first-page":"6","DOI":"10.3109\/07853890.2014.971052","volume":"47","author":"S Kadavath","year":"2015","unstructured":"Kadavath S, Efthimiou P (2015) Adult-onset Still\u2019s disease-pathogenesis, clinical manifestations, and new treatment options. Ann Med 47(1):6\u201314. https:\/\/doi.org\/10.3109\/07853890.2014.971052","journal-title":"Ann Med"},{"issue":"6","key":"5921_CR3","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1016\/j.semarthrit.2015.11.002","volume":"45","author":"A Lenert","year":"2016","unstructured":"Lenert A, Yao Q (2016) Macrophage activation syndrome complicating adult onset Still\u2019s disease: a single center case series and comparison with literature. Semin Arthritis Rheum 45(6):711\u2013716. https:\/\/doi.org\/10.1016\/j.semarthrit.2015.11.002","journal-title":"Semin Arthritis Rheum"},{"issue":"9","key":"5921_CR4","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1080\/1744666X.2017.1332994","volume":"13","author":"DH Yoo","year":"2017","unstructured":"Yoo DH (2017) Treatment of adult-onset Still\u2019s disease: up to date. Expert Rev Clin Immunol 13(9):849\u2013866. https:\/\/doi.org\/10.1080\/1744666X.2017.1332994","journal-title":"Expert Rev Clin Immunol"},{"issue":"2","key":"5921_CR5","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.berh.2016.08.003","volume":"30","author":"S Castaneda","year":"2016","unstructured":"Castaneda S, Blanco R, Gonzalez-Gay MA (2016) Adult-onset Still\u2019s disease: advances in the treatment. Best Pract Res Clin Rheumatol 30(2):222\u2013238. https:\/\/doi.org\/10.1016\/j.berh.2016.08.003","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"5921_CR6","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.jaut.2016.02.010","volume":"69","author":"U Kalyoncu","year":"2016","unstructured":"Kalyoncu U, Solmaz D, Emmungil H et al (2016) Response rate of initial conventional treatments, disease course, and related factors of patients with adult-onset Still\u2019s disease: data from a large multicenter cohort. J Autoimmun 69:59\u201363. https:\/\/doi.org\/10.1016\/j.jaut.2016.02.010","journal-title":"J Autoimmun"},{"issue":"11","key":"5921_CR7","first-page":"2422","volume":"30","author":"JH Choi","year":"2003","unstructured":"Choi JH, Suh CH, Lee YM et al (2003) Serum cytokine profiles in patients with adult onset Still\u2019s disease. J Rheumatol 30(11):2422\u20132427","journal-title":"J Rheumatol"},{"issue":"7","key":"5921_CR8","doi-asserted-by":"publisher","first-page":"1716","DOI":"10.1002\/1529-0131(200107)44:7<1716::AID-ART298>3.0.CO;2-I","volume":"44","author":"Y Kawaguchi","year":"2001","unstructured":"Kawaguchi Y, Terajima H, Harigai M, Hara M, Kamatani N (2001) Interleukin-18 as a novel diagnostic marker and indicator of disease severity in adult-onset Still\u2019s disease. Arthritis Rheum 44(7):1716\u20131717. https:\/\/doi.org\/10.1002\/1529-0131(200107)44:7%3c1716::AID-ART298%3e3.0.CO;2-I","journal-title":"Arthritis Rheum"},{"issue":"12","key":"5921_CR9","doi-asserted-by":"publisher","first-page":"2305","DOI":"10.1093\/rheumatology\/keq284","volume":"49","author":"DY Chen","year":"2010","unstructured":"Chen DY, Chen YM, Lan JL, Lin CC, Chen HH, Hsieh CW (2010) Potential role of Th17 cells in the pathogenesis of adult-onset Still\u2019s disease. Rheumatology (Oxford) 49(12):2305\u20132312. https:\/\/doi.org\/10.1093\/rheumatology\/keq284","journal-title":"Rheumatology (Oxford)"},{"issue":"8","key":"5921_CR10","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.3899\/jrheum.161354","volume":"44","author":"CW Hsieh","year":"2017","unstructured":"Hsieh CW, Chen YM, Lin CC et al (2017) Elevated expression of the NLRP3 inflammasome and its correlation with disease activity in adult-onset Still disease. J Rheumatol 44(8):1142\u20131150. https:\/\/doi.org\/10.3899\/jrheum.161354","journal-title":"J Rheumatol"},{"issue":"10","key":"5921_CR11","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1038\/s41584-018-0081-x","volume":"14","author":"E Feist","year":"2018","unstructured":"Feist E, Mitrovic S, Fautrel B (2018) Mechanisms, biomarkers and targets for adult-onset Still\u2019s disease. Nat Rev Rheumatol 14(10):603\u2013618. https:\/\/doi.org\/10.1038\/s41584-018-0081-x","journal-title":"Nat Rev Rheumatol"},{"key":"5921_CR12","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.clim.2016.05.010","volume":"169","author":"N Inoue","year":"2016","unstructured":"Inoue N, Shimizu M, Tsunoda S, Kawano M, Matsumura M, Yachie A (2016) Cytokine profile in adult-onset Still\u2019s disease: comparison with systemic juvenile idiopathic arthritis. Clin Immunol 169:8\u201313. https:\/\/doi.org\/10.1016\/j.clim.2016.05.010","journal-title":"Clin Immunol"},{"issue":"12","key":"5921_CR13","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1007\/s40265-018-0956-9","volume":"78","author":"P Sfriso","year":"2018","unstructured":"Sfriso P, Bindoli S, Galozzi P (2018) Adult-onset Still\u2019s disease: molecular pathophysiology and therapeutic advances. Drugs 78(12):1187\u20131195. https:\/\/doi.org\/10.1007\/s40265-018-0956-9","journal-title":"Drugs"},{"issue":"1","key":"5921_CR14","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1002\/acr.20319","volume":"63","author":"X Puechal","year":"2011","unstructured":"Puechal X, DeBandt M, Berthelot JM et al (2011) Tocilizumab in refractory adult Still\u2019s disease. Arthritis Care Res (Hoboken) 63(1):155\u2013159. https:\/\/doi.org\/10.1002\/acr.20319","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"1","key":"5921_CR15","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s10067-012-2105-2","volume":"32","author":"H de Boysson","year":"2013","unstructured":"de Boysson H, Fevrier J, Nicolle A, Auzary C, Geffray L (2013) Tocilizumab in the treatment of the adult-onset Still\u2019s disease: current clinical evidence. Clin Rheumatol 32(1):141\u2013147. https:\/\/doi.org\/10.1007\/s10067-012-2105-2","journal-title":"Clin Rheumatol"},{"issue":"6","key":"5921_CR16","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1002\/art.38398","volume":"66","author":"F Ortiz-Sanjuan","year":"2014","unstructured":"Ortiz-Sanjuan F, Blanco R, Calvo-Rio V et al (2014) Efficacy of tocilizumab in conventional treatment-refractory adult-onset Still\u2019s disease: multicenter retrospective open-label study of thirty-four patients. Arthritis Rheumatol 66(6):1659\u20131665. https:\/\/doi.org\/10.1002\/art.38398","journal-title":"Arthritis Rheumatol"},{"issue":"3","key":"5921_CR17","doi-asserted-by":"publisher","first-page":"401","DOI":"10.3109\/14397595.2014.973659","volume":"25","author":"N Nishina","year":"2015","unstructured":"Nishina N, Kaneko Y, Kameda H, Takeuchi T (2015) The effect of tocilizumab on preventing relapses in adult-onset Still\u2019s disease: a retrospective, single-center study. Mod Rheumatol 25(3):401\u2013404. https:\/\/doi.org\/10.3109\/14397595.2014.973659","journal-title":"Mod Rheumatol"},{"issue":"2","key":"5921_CR18","doi-asserted-by":"publisher","first-page":"297","DOI":"10.3109\/14397595.2014.899178","volume":"26","author":"E Bannai","year":"2016","unstructured":"Bannai E, Yamashita H, Kaneko S et al (2016) Successful tocilizumab therapy in seven patients with refractory adult-onset Still\u2019s disease. Mod Rheumatol 26(2):297\u2013301. https:\/\/doi.org\/10.3109\/14397595.2014.899178","journal-title":"Mod Rheumatol"},{"issue":"6 Suppl 102","key":"5921_CR19","first-page":"S64","volume":"34","author":"ST Song","year":"2016","unstructured":"Song ST, Kim JJ, Lee S et al (2016) Efficacy of tocilizumab therapy in Korean patients with adult-onset Still\u2019s disease: a multicentre retrospective study of 22 cases. Clin Exp Rheumatol 34(6 Suppl 102):S64\u2013S71","journal-title":"Clin Exp Rheumatol"},{"issue":"1","key":"5921_CR20","doi-asserted-by":"publisher","first-page":"13477","DOI":"10.1038\/s41598-017-13639-y","volume":"7","author":"T Li","year":"2017","unstructured":"Li T, Gu L, Wang X et al (2017) A pilot study on tocilizumab for treating refractory adult-onset Still\u2019s disease. Sci Rep 7(1):13477. https:\/\/doi.org\/10.1038\/s41598-017-13639-y","journal-title":"Sci Rep"},{"issue":"32","key":"5921_CR21","doi-asserted-by":"publisher","first-page":"e16682","DOI":"10.1097\/MD.0000000000016682","volume":"98","author":"CY Wang","year":"2019","unstructured":"Wang CY, Guo SH, Wang LP, Shen HL (2019) Refractory adult-onset Still disease treated by tocilizumab combined with methotrexate: a STROBE-compliant article. Medicine (Baltimore) 98(32):e16682. https:\/\/doi.org\/10.1097\/MD.0000000000016682","journal-title":"Medicine (Baltimore)"},{"issue":"4","key":"5921_CR22","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1080\/14712598.2019.1590334","volume":"19","author":"S Castaneda","year":"2019","unstructured":"Castaneda S, Martinez-Quintanilla D, Martin-Varillas JL, Garcia-Castaneda N, Atienza-Mateo B, Gonzalez-Gay MA (2019) Tocilizumab for the treatment of adult-onset Still\u2019s disease. Expert Opin Biol Ther 19(4):273\u2013286. https:\/\/doi.org\/10.1080\/14712598.2019.1590334","journal-title":"Expert Opin Biol Ther"},{"issue":"5","key":"5921_CR23","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1080\/14397595.2017.1416924","volume":"28","author":"Y Ma","year":"2018","unstructured":"Ma Y, Wu M, Zhang X et al (2018) Efficacy and safety of tocilizumab with inhibition of interleukin-6 in adult-onset Still\u2019s disease: a meta-analysis. Mod Rheumatol 28(5):849\u2013857. https:\/\/doi.org\/10.1080\/14397595.2017.1416924","journal-title":"Mod Rheumatol"},{"issue":"12","key":"5921_CR24","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1136\/annrheumdis-2018-213920","volume":"77","author":"Y Kaneko","year":"2018","unstructured":"Kaneko Y, Kameda H, Ikeda K et al (2018) Tocilizumab in patients with adult-onset Still\u2019s disease refractory to glucocorticoid treatment: a randomised, double-blind, placebo-controlled phase III trial. Ann Rheum Dis 77(12):1720\u20131729. https:\/\/doi.org\/10.1136\/annrheumdis-2018-213920","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"5921_CR25","doi-asserted-by":"publisher","first-page":"2530","DOI":"10.1002\/art.27532","volume":"62","author":"S Franchini","year":"2010","unstructured":"Franchini S, Dagna L, Salvo F, Aiello P, Baldissera E, Sabbadini MG (2010) Efficacy of traditional and biologic agents in different clinical phenotypes of adult-onset Still\u2019s disease. Arthritis Rheum 62(8):2530\u20132535. https:\/\/doi.org\/10.1002\/art.27532","journal-title":"Arthritis Rheum"},{"issue":"11","key":"5921_CR26","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1016\/j.autrev.2014.08.032","volume":"13","author":"AT Maria","year":"2014","unstructured":"Maria AT, Le Quellec A, Jorgensen C, Touitou I, Riviere S, Guilpain P (2014) Adult onset Still\u2019s disease (AOSD) in the era of biologic therapies: dichotomous view for cytokine and clinical expressions. Autoimmun Rev 13(11):1149\u20131159. https:\/\/doi.org\/10.1016\/j.autrev.2014.08.032","journal-title":"Autoimmun Rev"},{"issue":"1","key":"5921_CR27","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s13075-019-1838-6","volume":"21","author":"F Vercruysse","year":"2019","unstructured":"Vercruysse F, Barnetche T, Lazaro E et al (2019) Adult-onset Still\u2019s disease biological treatment strategy may depend on the phenotypic dichotomy. Arthritis Res Ther 21(1):53. https:\/\/doi.org\/10.1186\/s13075-019-1838-6","journal-title":"Arthritis Res Ther"},{"issue":"3","key":"5921_CR28","first-page":"424","volume":"19","author":"M Yamaguchi","year":"1992","unstructured":"Yamaguchi M, Ohta A, Tsunematsu T et al (1992) Preliminary criteria for classification of adult Still\u2019s disease. J Rheumatol 19(3):424\u2013430","journal-title":"J Rheumatol"},{"issue":"11","key":"5921_CR29","doi-asserted-by":"publisher","first-page":"2369","DOI":"10.3899\/jrheum.100247","volume":"37","author":"M Rau","year":"2010","unstructured":"Rau M, Schiller M, Krienke S, Heyder P, Lorenz H, Blank N (2010) Clinical manifestations but not cytokine profiles differentiate adult-onset Still\u2019s disease and sepsis. J Rheumatol 37(11):2369\u20132376. https:\/\/doi.org\/10.3899\/jrheum.100247","journal-title":"J Rheumatol"},{"issue":"1","key":"5921_CR30","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1002\/art.1780380107","volume":"38","author":"ML Prevoo","year":"1995","unstructured":"Prevoo ML, van \u2019t Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL (1995) Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 38(1):44\u201348. https:\/\/doi.org\/10.1002\/art.1780380107","journal-title":"Arthritis Rheum"},{"issue":"4","key":"5921_CR31","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1136\/ard.2009.123919","volume":"69","author":"JS Smolen","year":"2010","unstructured":"Smolen JS, Aletaha D, Bijlsma JW et al (2010) Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 69(4):631\u2013637. https:\/\/doi.org\/10.1136\/ard.2009.123919","journal-title":"Ann Rheum Dis"},{"key":"5921_CR32","unstructured":"CTEP cancer therapy evaluation program (2017) Common Terminology Criteria for Adverse Events (CTCAE) versions 5.0. National Cancer Institute. https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/ctc.htm#ctc_50. Accessed 17 August 2021"},{"issue":"1","key":"5921_CR33","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s10067-013-2381-5","volume":"33","author":"P Cipriani","year":"2014","unstructured":"Cipriani P, Ruscitti P, Carubbi F et al (2014) Tocilizumab for the treatment of adult-onset Still\u2019s disease: results from a case series. Clin Rheumatol 33(1):49\u201355. https:\/\/doi.org\/10.1007\/s10067-013-2381-5","journal-title":"Clin Rheumatol"},{"issue":"16","key":"5921_CR34","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.2169\/internalmedicine.50.4771","volume":"50","author":"Y Yoshida","year":"2011","unstructured":"Yoshida Y, Sakamoto M, Yokota K, Sato K, Mimura T (2011) Tocilizumab improved both clinical and laboratory manifestations except for interleukin-18 in a case of multiple drug-resistant adult-onset Still\u2019s disease. Intern Med 50(16):1757\u20131760. https:\/\/doi.org\/10.2169\/internalmedicine.50.4771","journal-title":"Intern Med"},{"issue":"3","key":"5921_CR35","doi-asserted-by":"publisher","first-page":"e13936","DOI":"10.1111\/ijcp.13936","volume":"75","author":"S Kir","year":"2021","unstructured":"Kir S, Ozgen M, Zontul S (2021) Adult-onset Still\u2019s disease and treatment results with tocilizumab. Int J Clin Pract 75(3):e13936. https:\/\/doi.org\/10.1111\/ijcp.13936","journal-title":"Int J Clin Pract"},{"issue":"5","key":"5921_CR36","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1002\/jcla.21908","volume":"30","author":"R Mercan","year":"2016","unstructured":"Mercan R, Bitik B, Tufan A et al (2016) The association between neutrophil\/lymphocyte ratio and disease activity in rheumatoid arthritis and ankylosing spondylitis. J Clin Lab Anal 30(5):597\u2013601. https:\/\/doi.org\/10.1002\/jcla.21908","journal-title":"J Clin Lab Anal"},{"issue":"29","key":"5921_CR37","doi-asserted-by":"publisher","first-page":"e7546","DOI":"10.1097\/MD.0000000000007546","volume":"96","author":"JY Seo","year":"2017","unstructured":"Seo JY, Suh CH, Jung JY, Kim AR, Yang JW, Kim HA (2017) The neutrophil-to-lymphocyte ratio could be a good diagnostic marker and predictor of relapse in patients with adult-onset Still\u2019s disease: a STROBE-compliant retrospective observational analysis. Medicine (Baltimore) 96(29):e7546. https:\/\/doi.org\/10.1097\/MD.0000000000007546","journal-title":"Medicine (Baltimore)"},{"key":"5921_CR38","doi-asserted-by":"publisher","first-page":"167","DOI":"10.2147\/TCRM.S155488","volume":"14","author":"S Zhou","year":"2018","unstructured":"Zhou S, Qiao J, Bai J, Wu Y, Fang H (2018) Biological therapy of traditional therapy-resistant adult-onset Still\u2019s disease: an evidence-based review. Ther Clin Risk Manag 14:167\u2013171. https:\/\/doi.org\/10.2147\/TCRM.S155488","journal-title":"Ther Clin Risk Manag"},{"issue":"39","key":"5921_CR39","doi-asserted-by":"publisher","first-page":"e1554","DOI":"10.1097\/MD.0000000000001554","volume":"94","author":"F Ortiz-Sanjuan","year":"2015","unstructured":"Ortiz-Sanjuan F, Blanco R, Riancho-Zarrabeitia L et al (2015) Efficacy of anakinra in refractory adult-onset Still\u2019s disease: multicenter study of 41 patients and literature review. Medicine (Baltimore) 94(39):e1554. https:\/\/doi.org\/10.1097\/MD.0000000000001554","journal-title":"Medicine (Baltimore)"},{"issue":"11","key":"5921_CR40","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1080\/14712598.2019.1652591","volume":"19","author":"DH Yoo","year":"2019","unstructured":"Yoo DH (2019) Biologics for the treatment of adult-onset Still\u2019s disease. Expert Opin Biol Ther 19(11):1173\u20131190. https:\/\/doi.org\/10.1080\/14712598.2019.1652591","journal-title":"Expert Opin Biol Ther"},{"issue":"4","key":"5921_CR41","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1002\/acr.22194","volume":"66","author":"H Ichida","year":"2014","unstructured":"Ichida H, Kawaguchi Y, Sugiura T et al (2014) Clinical manifestations of adult-onset Still\u2019s disease presenting with erosive arthritis: association with low levels of ferritin and interleukin-18. Arthritis Care Res (Hoboken) 66(4):642\u2013646. https:\/\/doi.org\/10.1002\/acr.22194","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"5","key":"5921_CR42","doi-asserted-by":"publisher","first-page":"910","DOI":"10.3390\/jcm10050910","volume":"10","author":"SW Nam","year":"2021","unstructured":"Nam SW, Kang SM, Lee JH, Yoo DH (2021) Different features of interleukin-37 and interleukin-18 as disease activity markers of adult-onset Still\u2019s disease. J Clin Med 10(5):910. https:\/\/doi.org\/10.3390\/jcm10050910","journal-title":"J Clin Med"},{"issue":"2","key":"5921_CR43","doi-asserted-by":"publisher","first-page":"162","DOI":"10.3109\/03009742.2013.824023","volume":"43","author":"KH Jung","year":"2014","unstructured":"Jung KH, Kim JJ, Lee JS et al (2014) Interleukin-18 as an efficient marker for remission and follow-up in patients with inactive adult-onset Still\u2019s disease. Scand J Rheumatol 43(2):162\u2013169. https:\/\/doi.org\/10.3109\/03009742.2013.824023","journal-title":"Scand J Rheumatol"},{"issue":"3","key":"5921_CR44","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1080\/14397595.2016.1221875","volume":"27","author":"Y Tsuchida","year":"2017","unstructured":"Tsuchida Y, Sumitomo S, Shoda H, Kubo K, Fujio K, Yamamoto K (2017) Macrophage activation syndrome associated with tocilizumab treatment in adult-onset Still\u2019s disease. Mod Rheumatol 27(3):556\u2013557. https:\/\/doi.org\/10.1080\/14397595.2016.1221875","journal-title":"Mod Rheumatol"},{"issue":"1","key":"5921_CR45","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1007\/s10165-010-0348-9","volume":"21","author":"M Kobayashi","year":"2011","unstructured":"Kobayashi M, Takahashi Y, Yamashita H, Kaneko H, Mimori A (2011) Benefit and a possible risk of tocilizumab therapy for adult-onset Still\u2019s disease accompanied by macrophage-activation syndrome. Mod Rheumatol 21(1):92\u201396. https:\/\/doi.org\/10.1007\/s10165-010-0348-9","journal-title":"Mod Rheumatol"},{"issue":"8","key":"5921_CR46","doi-asserted-by":"publisher","first-page":"2379","DOI":"10.1007\/s10067-020-04949-0","volume":"39","author":"R Wang","year":"2020","unstructured":"Wang R, Li T, Ye S et al (2020) Macrophage activation syndrome associated with adult-onset Still\u2019s disease: a multicenter retrospective analysis. Clin Rheumatol 39(8):2379\u20132386. https:\/\/doi.org\/10.1007\/s10067-020-04949-0","journal-title":"Clin Rheumatol"},{"key":"5921_CR47","doi-asserted-by":"publisher","unstructured":"Yamabe T, Ohmura SI, Uehara K, Naniwa T (2021) Macrophage activation syndrome in patients with adult-onset Still\u2019s disease under tocilizumab treatment: a single-center observational study. Mod Rheumatol:1\u20138. https:\/\/doi.org\/10.1080\/14397595.2021.1899565","DOI":"10.1080\/14397595.2021.1899565"},{"issue":"6","key":"5921_CR48","doi-asserted-by":"publisher","first-page":"864","DOI":"10.3899\/jrheum.170955","volume":"45","author":"P Ruscitti","year":"2018","unstructured":"Ruscitti P, Iacono D, Ciccia F et al (2018) Macrophage activation syndrome in patients affected by adult-onset Still disease: analysis of survival rates and predictive factors in the Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale Cohort. J Rheumatol 45(6):864\u2013872. https:\/\/doi.org\/10.3899\/jrheum.170955","journal-title":"J Rheumatol"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-021-05921-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-021-05921-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-021-05921-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T01:58:35Z","timestamp":1659059915000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-021-05921-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,17]]},"references-count":48,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["5921"],"URL":"https:\/\/doi.org\/10.1007\/s10067-021-05921-2","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,17]]},"assertion":[{"value":"18 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}